CytoMed Therapeutics (GDTC) announced the completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025. The ANGELICA Trial evaluates the safety and tolerability of allogeneic NKG2DL-targeting chimeric antigen receptor-grafted gamma delta T cells in the treatment of a basket of cancer indications that include advanced solid and haematological malignancies. Refer to our announcement on Form 6K on October 7, 2024 for more information regarding the ANGELICA Trial.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDTC: